MiNK Therapeutics Targets Immune Reconstitution to Combat Advanced Gastroesophageal Cancers with Novel Combination of Allo-iNKTs plus BOT/BAL at ASCO GI
24 1월 2025 - 4:13AM
MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage
biopharmaceutical company pioneering the development of allogeneic,
off-the-shelf invariant natural killer T (iNKT) cell therapies to
treat cancer and other immune-mediated diseases, today announced a
presentation at the American Society of Clinical Oncology
Gastrointestinal Cancers (ASCO GI) Symposium in San Francisco,
California.
“INKT cells play a pivotal role in reconstituting
lymphocytes, establishing a robust and responsive immune
environment to address the complexities of advanced cancers.
Agenus’ botensilimab/balstilimab combination (BOT/BAL) amplifies
this effect by enhancing T-cell priming, eliminating
immunosuppressive regulatory cells, and fostering long-term immune
memory. This novel multi-immune combination treats the immune
system itself, fundamentally reshaping the tumor environment to
make disease biologically unsustainable,” said Dr. Jennifer Buell,
Chief Executive Officer at MiNK Therapeutics. “We look forward to
sharing further results from this study later this year.”
Phase 2 AgenT-797 plus BOT/BAL in
Combination with Ramucirumab and Paclitaxel in Patients with
Previously Treated, Unresectable or Metastatic Gastroesophageal
Cancers (Abstract TPS515)
- This investigator-initiated, single-arm Phase 2 trial,
conducted at Memorial Sloan Kettering Cancer Center (NCT06251793),
evaluates the novel combination of agenT-797 (iNKT cells),
botensilimab, balstilimab, ramucirumab, and paclitaxel in advanced
GE adenocarcinoma patients who have received at least one prior
line of therapy.
- Data from the prior Phase I trial (NCT05108623) demonstrated
long-term, durable responses and tolerability in PD-1 refractory
relapsed/refractory cancers, including testicular, appendiceal,
lung, and gastric cancers. Notably, gastric cancer patients
exhibited significant clinical and immunologic responses, including
robust T cell infiltration and expansion compared to
non-responders.
- This novel, multi-immunologic combination demonstrated signals
of tolerability and activity in patients with relapsed/refractory
gastric cancer. MiNK plans to provide a clinical update from the
ongoing Phase II study in the second half of 2025.
The presentation will be available on the
publications page of the MiNK website at the start of the scheduled
presentation session at
https://minktherapeutics.com/publications/.
Presentation Details
Abstract Title: A phase II
study of agenT-797 (invariant natural killer T-cells), botensilimab
(Fc-enhanced CTLA-4 inhibitor) and balstilimab (anti-PD-1) in
patients with advanced, refractory gastroesophageal
adenocarcinomaAbstract
Number: TPS515Presenting
Author: Dr. Samuel
CytrynSession: Trials in Progress Poster
Session A: Cancers of the Esophagus and Stomach and Other
Gastrointestinal CancersSession Date and
Time: 1/23/2025, 11:30 AM-1:00 PM PST
About MiNK Therapeutics
MiNK Therapeutics is a clinical-stage
biopharmaceutical company pioneering the discovery, development,
and commercialization of allogeneic invariant natural killer T
(iNKT) cell therapies to treat cancer and other immune-mediated
diseases. MiNK is advancing a pipeline of both native and next
generation engineered iNKT programs, with a platform designed to
facilitate scalable and reproducible manufacturing for
off-the-shelf delivery. The company is headquartered in New
York, NY. For more information,
visit https://minktherapeutics.com/ or @MiNK_iNKT.
Information that may be important to investors will be routinely
posted on our website and social media channels.
Forward Looking Statements
This press release contains forward-looking
statements that are made pursuant to the safe harbor provisions of
the federal securities laws, including statements regarding the
therapeutic potential, anticipated benefit, plans and timelines of
iNKT cells and encrypted RNA, as well as the collaboration between
MiNK and Autonomous Therapeutics. These forward-looking statements
are subject to risks and uncertainties that could cause actual
results to differ materially. These forward-looking statements are
subject to risks and uncertainties, including the factors described
under the Risk Factors section of the most recent Form 10-K, Form
10-Q and the S-1 Registration Statement filed with the SEC.
MiNK cautions investors not to place considerable reliance on the
forward-looking statements contained in this release. These
statements speak only as of the date of this press release, and
MiNK and Autonomous undertake no obligation to update or revise the
statements, other than to the extent required by law. All
forward-looking statements are expressly qualified in their
entirety by this cautionary statement.
Investor
Contact917-362-1370investor@minktherapeutics.com
Media
Contact781-674-4428communications@minktherapeutics.com
MiNK Therapeutics (NASDAQ:INKT)
과거 데이터 주식 차트
부터 1월(1) 2025 으로 2월(2) 2025
MiNK Therapeutics (NASDAQ:INKT)
과거 데이터 주식 차트
부터 2월(2) 2024 으로 2월(2) 2025